Loading company
Just reported
Q3 2026 results
From Immunome's results release of November 9, 2026; its quarterly report has since been filed.
Revenue
Actual
$0.00
Guided
—
No guide given
EPS, GAAP
Actual
-$0.76
Guided
—
No guide given
Operating income, GAAP
Actual
-$90.4M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Immunome is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now A
How it makes money
- Research collaboration payments (historical)
Competes with
- MKKGYMerck KGaA (through SpringWorks Therapeutics)
- MRKMerck & Co.A
- Size
- $364.3B
- Margin
- 3.6%
- 2616CStone Pharmaceuticals
- NVSNovartisA
- Size
- $306.3B
- Margin
- -0.1%
- CATXPerspective Therapeutics
- Size
- $114.3M
- Ratio Therapeutics
What it sells6
Varegacestat
An investigational, once-daily pill being developed to treat desmoid tumors, which can grow into nearby tissue.
IM-1021
An experimental antibody-drug conjugate designed to carry cancer-killing medicine to cells with the ROR1 marker; it is being tested in people with lymphoma and solid tumors.
IM-1617
An experimental antibody-drug conjugate designed to target a receptor found on some solid tumors.
Show 3 more
IM-3050
An experimental treatment that uses a molecule aimed at the FAP marker to deliver radioactive lutetium-177 to cells in solid tumors.
IM-1340
An experimental antibody-drug conjugate being developed for solid tumors, including some lung and prostate cancers.
IM-1335
An experimental antibody-drug conjugate being developed to treat solid tumors; its target has not been publicly named.
Who buys it1
- AbbVie paid for research work under a collaboration agreement that ended in July 2025 (high confidence); Immunome has not reported product-sale customers.
What it stands on, and what could break it
What the business leans on
- 1Immunome relies on outside manufacturers for materials used in its named drug programs and expects to rely on them for future commercial supply.
- 2The IM-3050 clinical trial depends on third-party diagnostic radiotracer supply; its treatment also requires radioactive lutetium-177.
- 3Varegacestat is licensed from Bristol Myers Squibb, and Immunome owes that company royalties and potential milestone payments if the drug is developed and sold.
What could go wrong
- 1Varegacestat has not received marketing approval; the Food and Drug Administration could reject its application or require more information before a decision.
- 2Immunome has no product-sale revenue, reports continuing losses, and expects to need additional financing to fund development and potential commercialization.
- 3Drug development results are uncertain: clinical trials may not show adequate safety or benefit, and early results may not predict later trial outcomes.
About Immunome Inc.
Immunome develops medicines intended to treat cancer. Its main drug candidate, varegacestat, is an investigational pill for desmoid tumors; the company has submitted a marketing application in the United States. Its other experimental treatments include drugs designed to deliver cancer-killing medicine or radiation to tumors.
- Head office
- Exton, Pennsylvania, United States
- Founded
- 2006
- Listed on
- Nasdaq
- Financial year ends
- December 31
Built from Immunome Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
